Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction carcinoma who may be eligible for treatment with KEYTRUDA, Merck's ( MRK ) anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indicated to identify patients with esophageal or GEJ carcinoma whose tumors express PD-L1 who may be eligible for treatment with KEYTRUDA. This approval marks the eighth FDA approved companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006, for use with KEYTRUDA. “With the expanded FDA approval of PD-L1 IHC 22C3 pharmDx in esophageal or GEJ carcinoma, Agilent is proud to support clinicians in identifying patients eligible for treatment with KEYTRUDA,” said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division. “This milestone reinforces Agilent's commitment to advan
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Jim Cramer on Merck & Co.: “If We're Really Going Into an Oil Shock-Induced Slowdown, I Think This One's Likely an Outperformer”” [Yahoo! Finance]Yahoo! Finance
- Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition [Yahoo! Finance]Yahoo! Finance
- Merck's deal for Terns sparks debate over a possible biotech bidding war [Yahoo! Finance]Yahoo! Finance
- RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium” [Yahoo! Finance]Yahoo! Finance
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline [MSNBC.com]MSNBC.com
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- MRK's page on the SEC website